26P Liquid biopsy as promising source of plasma extracellular vesicle biomarkers of response to cabozantinib (CABO) plus durvalumab (DURVA) in advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) patients (the phase II ARCADIA trial)

Saved in:
Bibliographic Details
Published inImmuno-oncology technology Vol. 20; p. 100495
Main Authors Huber, V., Mereu, A., Lalli, L., Salsetta, J., Banfi, C., Squarcina, P., Sgambelluri, F., Mortarini, R., Stellato, M., Raggi, D., Guadalupi, V., Claps, M., Ferrari Bravo, W., Calareso, G., Alessi, A., Anichini, A., Procopio, G., Necchi, A., Rivoltini, L., Giannatempo, P.
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.12.2023
Online AccessGet full text

Cover

More Information
ISSN:2590-0188
2590-0188
DOI:10.1016/j.iotech.2023.100495